Literature DB >> 24727484

CHRNA5 variant predicts smoking cessation in patients with acute myocardial infarction.

Li-Shiun Chen1, Richard G Bach2, Petra A Lenzini3, John A Spertus4, Laura Jean Bierut1, Sharon Cresci5.   

Abstract

INTRODUCTION: While smoking is a major modifiable risk factor for secondary prevention of myocardial infarction (MI), active smoking is common among patients hospitalized with acute MI. Recent studies suggest that nicotinic receptor variants, and specifically the high-risk CHRNA5 rs16969968 A allele, are associated with cessation failure among noncardiac patients. This study investigates the association between CHRNA5 rs16969968 and smoking cessation in patients hospitalized with acute MI.
METHODS: Using data from the TRIUMPH study, we ascertained smoking status at the time of index hospitalization for acute MI and 1 year after hospitalization. After adjusting for age and sex, we used logistic regression to model the association between smoking cessation and CHRNA5 rs16969968.
RESULTS: At index admission, 752 Caucasian subjects were active smokers and 699 were former smokers. Among these ever-smokers, the A allele was associated with significantly decreased abstinence (45.0% abstinence for A allele carriers vs. 51.7% for GG homozygotes; odds ratio [OR] = 0.70, 95% confidence interval [CI] = 0.56-0.88, p = .0027). The A allele was also significantly associated with decreased abstinence at 1 year (69.1% abstinence for A allele carriers vs. 76.0% for GG homozygotes; OR = 0.70, 95% CI = 0.53-0.94, p = .0185).
CONCLUSIONS: Among patients who have smoked and who are hospitalized with acute MI, the high-risk CHRNA5 allele was associated with lower likelihood of quitting before hospitalization and significantly less abstinence 1 year after hospitalization with MI. The CHRNA5 rs16969968 genotype may therefore identify patients who would benefit from aggressive, personalized smoking cessation intervention.
© The Author 2014. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24727484      PMCID: PMC4155476          DOI: 10.1093/ntr/ntu059

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  35 in total

1.  Biochemical verification of tobacco use and cessation.

Authors: 
Journal:  Nicotine Tob Res       Date:  2002-05       Impact factor: 4.244

2.  Prospective association of dopamine-related polymorphisms with smoking cessation in general care.

Authors:  Lutz P Breitling; Dorothee Twardella; Michael M Hoffmann; Stephanie H Witt; Jens Treutlein; Hermann Brenner
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

3.  Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success.

Authors:  Li-Shiun Chen; Timothy B Baker; Megan E Piper; Naomi Breslau; Dale S Cannon; Kimberly F Doheny; Stephanie M Gogarten; Eric O Johnson; Nancy L Saccone; Jen C Wang; Robert B Weiss; Alison M Goate; Laura Jean Bierut
Journal:  Am J Psychiatry       Date:  2012-07       Impact factor: 18.112

4.  Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy.

Authors:  Jane E Sarginson; Joel D Killen; Laura C Lazzeroni; Stephen P Fortmann; Heather S Ryan; Alan F Schatzberg; Greer M Murphy
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-01-25       Impact factor: 3.568

5.  Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH): design and rationale of a prospective multicenter registry.

Authors:  Suzanne V Arnold; Paul S Chan; Philip G Jones; Carole Decker; Donna M Buchanan; Harlan M Krumholz; P Michael Ho; John A Spertus
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-07

6.  The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease.

Authors:  A M Joseph; S M Norman; L H Ferry; A V Prochazka; E C Westman; B G Steele; S E Sherman; M Cleveland; D O Antonuccio; D O Antonnucio; N Hartman; P G McGovern
Journal:  N Engl J Med       Date:  1996-12-12       Impact factor: 91.245

7.  Genome-wide meta-analyses identify multiple loci associated with smoking behavior.

Authors: 
Journal:  Nat Genet       Date:  2010-04-25       Impact factor: 38.330

8.  Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD.

Authors:  Nancy L Saccone; Robert C Culverhouse; Tae-Hwi Schwantes-An; Dale S Cannon; Xiangning Chen; Sven Cichon; Ina Giegling; Shizhong Han; Younghun Han; Kaisu Keskitalo-Vuokko; Xiangyang Kong; Maria Teresa Landi; Jennie Z Ma; Susan E Short; Sarah H Stephens; Victoria L Stevens; Lingwei Sun; Yufei Wang; Angela S Wenzlaff; Steven H Aggen; Naomi Breslau; Peter Broderick; Nilanjan Chatterjee; Jingchun Chen; Andrew C Heath; Markku Heliövaara; Nicole R Hoft; David J Hunter; Majken K Jensen; Nicholas G Martin; Grant W Montgomery; Tianhua Niu; Thomas J Payne; Leena Peltonen; Michele L Pergadia; John P Rice; Richard Sherva; Margaret R Spitz; Juzhong Sun; Jen C Wang; Robert B Weiss; William Wheeler; Stephanie H Witt; Bao-Zhu Yang; Neil E Caporaso; Marissa A Ehringer; Tim Eisen; Susan M Gapstur; Joel Gelernter; Richard Houlston; Jaakko Kaprio; Kenneth S Kendler; Peter Kraft; Mark F Leppert; Ming D Li; Pamela A F Madden; Markus M Nöthen; Sreekumar Pillai; Marcella Rietschel; Dan Rujescu; Ann Schwartz; Christopher I Amos; Laura J Bierut
Journal:  PLoS Genet       Date:  2010-08-05       Impact factor: 5.917

9.  A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies.

Authors:  Megan E Piper; Stevens S Smith; Tanya R Schlam; Michael C Fiore; Douglas E Jorenby; David Fraser; Timothy B Baker
Journal:  Arch Gen Psychiatry       Date:  2009-11

10.  Identification of barriers that impede the implementation of nicotine replacement therapy in the acute cardiac care setting.

Authors:  Fiona C May; Nigel Stocks; Christopher Barton
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2008-12
View more
  7 in total

1.  A novel genetic marker of decreased inflammation and improved survival after acute myocardial infarction.

Authors:  Edward D Coverstone; Richard G Bach; LiShiun Chen; Laura J Bierut; Allie Y Li; Petra A Lenzini; Heidi C O'Neill; John A Spertus; Carmen C Sucharov; Jerry A Stitzel; Joel D Schilling; Sharon Cresci
Journal:  Basic Res Cardiol       Date:  2018-08-10       Impact factor: 17.165

Review 2.  Toward the implementation of genomic applications for smoking cessation and smoking-related diseases.

Authors:  Alex T Ramsey; Li-Shiun Chen; Sarah M Hartz; Nancy L Saccone; Sherri L Fisher; Enola K Proctor; Laura J Bierut
Journal:  Transl Behav Med       Date:  2018-01-29       Impact factor: 3.046

Review 3.  Contribution of Variants in CHRNA5/A3/B4 Gene Cluster on Chromosome 15 to Tobacco Smoking: From Genetic Association to Mechanism.

Authors:  Li Wen; Keran Jiang; Wenji Yuan; Wenyan Cui; Ming D Li
Journal:  Mol Neurobiol       Date:  2014-12-05       Impact factor: 5.590

Review 4.  Pathways to precision medicine in smoking cessation treatments.

Authors:  Li-Shiun Chen; Amy Horton; Laura Bierut
Journal:  Neurosci Lett       Date:  2016-05-18       Impact factor: 3.046

5.  Smoking Interacts With CHRNA5, a Nicotinic Acetylcholine Receptor Subunit Gene, to Influence the Risk of IBD-Related Surgery.

Authors:  Kelly C Cushing; Adeeti Chiplunker; Allie Li; Yun Ju Sung; Taylor Geisman; Li-Shiun Chen; Sharon Cresci; Alexandra M Gutierrez
Journal:  Inflamm Bowel Dis       Date:  2018-04-23       Impact factor: 5.325

6.  Kynurenine 3-Monooxygenase Gene Associated With Nicotine Initiation and Addiction: Analysis of Novel Regulatory Features at 5' and 3'-Regions.

Authors:  Hassan A Aziz; Abdel-Salam G Abdel-Salam; Mohammed A I Al-Obaide; Hytham W Alobydi; Saif Al-Humaish
Journal:  Front Genet       Date:  2018-06-13       Impact factor: 4.599

7.  Re-defininG AddiC(CH3)Tion: genomics and epigenomics on substance use disorders.

Authors:  Joni L Rutter; Nora D Volkow
Journal:  Mol Genet Genomic Med       Date:  2014-07-10       Impact factor: 2.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.